Securities Class Action Filed Against Aardvark Therapeutics
Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, has notified investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit. Investors who purchased the company's stock may be eligible to join the action.
San Francisco, CA – August 20, 2026 – A national shareholder rights law firm, Hagens Berman Sobol Shapiro LLP, has informed investors of Aardvark Therapeutics, Inc. (NASDAQ: AARD) regarding a securities class action lawsuit. The suit alleges that the company and its management may have violated federal securities laws through alleged misstatements and omissions.
According to the lawsuit, Aardvark Therapeutics and its officers purportedly made false and misleading statements about the company's business, operations, and prospects. Investors who purchased or acquired Aardvark common stock within a specified period are urged to contact the law firm to learn more about their rights and potential involvement in the class action.
The legal action has been filed in federal court. The complaint seeks to recover damages for investors who were allegedly harmed by the defendants' conduct. Aardvark Therapeutics has not yet formally responded to the allegations, and the outcome of the litigation could have significant financial implications for the company.
Shareholders are advised to review the details of the complaint and consider their legal options. The firm is investigating potential claims related to the company's public disclosures. The resolution of this case could impact Aardvark Therapeutics' stock.